What Спазго Treats: Main Uses and Benefits

Спазго is indicated for the temporary management of various discomforts associated with spasmodic and painful conditions. The medicine is used to help relieve symptoms of headache, toothache, migraine, neuralgia, arthralgia (joint pain), myalgia (muscle pain), primary dysmenorrhea (menstrual pain), and discomfort associated with smooth muscle spasms, such as biliary or renal colic.

This combination of actions may assist in the symptomatic management of clinical scenarios where acute pain is linked to cramps. The goal of administration is to support comfort, assisting the patient in managing episodes of acute discomfort.

“Timely intervention can support comfort during painful episodes.”

---

Quick Fact: Relief for Spasms and Pain

(Word Count: 109)

Eligibility and Contraindications

Official regulatory documentation establishes specific populations who are eligible to use Спазго (Dicyclomine) and those who are strictly prohibited. The medicine is primarily indicated for use in adults for conditions such as functional bowel syndrome.

Absolute Contraindications

The medicine must not be used in the following populations:

• Infants under 6 months of age.
• Nursing mothers (breastfeeding women).
• Patients with glaucoma.
• Patients with myasthenia gravis.
• Patients with obstructive diseases of the gastrointestinal or urinary tract.
• Patients with severe ulcerative colitis or reflux esophagitis.

Age-Related and Condition-Based Restrictions

Age Group	Eligibility Status
Pediatric Patients (> 6 months)	Safety and effectiveness have not been established.
Older Adults (Geriatric)	Use with caution; may be more susceptible to effects.
Pregnancy	Use is documented only if clearly needed.

Furthermore, use requires caution and is restricted in patients with hepatic (liver) or renal (kidney) impairment, autonomic neuropathy, and certain underlying cardiovascular conditions (e.g., tachyarrhythmia, coronary heart disease).

Interactions with Other Medicines and Products

The official regulatory documentation for Dicyclomine hydrochloride defines its interaction profile based on its anticholinergic properties, resulting in both pharmacodynamic and exposure-modifying interaction classifications. The overall interaction pattern is a clinically significant consideration for co-administered agents.

Additive Pharmacodynamic Effects

Co-administration with other anticholinergic agents (which includes various antihistamines, tricyclic antidepressants, and certain antiarrhythmic agents) may result in additive anticholinergic effects. This requires caution as it increases the overall burden of anticholinergic activity. The medicine also exhibits a pharmacodynamic antagonism by counteracting the effects of drugs that promote gastrointestinal motility, such as Metoclopramide.

Exposure Modification and Timing Rules

Dicyclomine's effect on the gastrointestinal tract alters the absorption of some co-administered products. Taking it with Antacids may interfere with absorption of dicyclomine itself, and the label specifies that simultaneous use should be avoided to prevent reduced exposure. Conversely, co-use with slowly dissolving dosage forms of Digoxin may increase serum digoxin concentration, carrying a risk of toxicity due to altered absorption dynamics.

Substance and Population Considerations

The regulatory label notes that co-use with alcohol can increase the risk of central nervous system effects, specifically dizziness or fainting. Furthermore, specific populations are noted as potentially more susceptible: the geriatric population and patients with impaired renal function may experience a greater risk of adverse anticholinergic interaction effects.

Disrupting Involuntary Nerve Signals via Receptor Blockade

The core mechanism of Спазго (Dicyclomine hydrochloride) involves competitive antagonism at Muscarinic Acetylcholine Receptors predominantly located on smooth muscle cells. By blocking the binding of the neurotransmitter acetylcholine, the drug interrupts nerve signals originating from the Parasympathetic Nervous System that command muscle contraction, leading to a reduction in muscle tone.

Modulating the Cellular Trigger for Contraction

This molecular blockade generates a cascade that reduces the availability of calcium ions ( Ca^2+) inside the muscle cell, which are critical for initiating contraction. This primary effect is complemented by a direct myotropic action that lowers the intrinsic excitability of the muscle fiber, which leads to a systemic reduction of muscle tone and a decrease in gastrointestinal motility.

Mechanistic Boundaries and Action Specificity

The drug's action is confined to these cholinergic and smooth muscle pathways, meaning its physiological effect is highly specific to modulating systems where muscle overactivity is driven by cholinergic signaling. It modulates systems that permit targeted pathway adjustment, but its mechanism possesses no primary action for modulating nociceptive signals that arise from sources other than muscle contraction.

The administration of Спазго (Dicyclomine hydrochloride) is defined by specific guidelines regarding its route, dosage frequency, and duration.

Dicyclomine is approved for two methods of administration: oral (using tablets or solution) and intramuscular (IM) injection. The injectable form is strictly restricted to the IM route and must not be administered intravenously or subcutaneously due to procedural constraints and risks. The IM route is intended for short-term use only and must be replaced by oral therapy within a maximum of one to two days.

The standard adult regimen requires a fixed schedule of four times a day (qid) for both the oral and IM forms. The initial oral dose is 20 mg qid. This may be escalated to the maximum maintenance oral dose of 40 mg qid, which amounts to a maximum daily dose of 160 mg. This dose titration, if needed, typically occurs after the first week of treatment.

For oral use, the treating professional assesses efficacy after two weeks. If the oral solution is utilized, the instructions require that the solution be diluted with an equal volume of water immediately prior to administration. For specific populations, caution is advised for patients with hepatic or renal impairment, though no specific dose adjustments are provided.

Research Evidence / Overview of Studies for Спазго

Evidence for Functional Bowel Disorder and Spasms

The active ingredient in Спазго, Dicyclomine, was studied for use in functional bowel disorder, particularly Irritable Bowel Syndrome (IBS). The primary research base includes short-term Randomized Controlled Trials (RCTs) that compared the drug to an inactive substance (placebo). This evidence is supplemented by systematic reviews and meta-analyses that aggregate findings from these trials. This research involved study populations experiencing outcomes related to physical discomfort, specifically abdominal pain and cramping.

In these studies, researchers monitored patient-reported outcomes describing perceived discomfort and overall global assessment of the patient’s condition. Research reports changes measured during the study period in symptom severity. However, regulatory reviews indicate that the evidence quality varies across studies, and some trials reported that findings were mixed regarding global symptom assessment scores when compared against placebo. The evidence contributes to the broader research landscape; however, it is generally assigned a low level of certainty by scientific bodies.

---

Long-Term Research and Follow-up

The majority of clinical studies that informed the regulatory evaluation of Dicyclomine were conducted over limited follow-up durations, typically ranging from two to eight weeks. This means that the characterization of long-term outcomes remains incomplete, and the profile of sustained use beyond the short trial period is not well documented.

What Remains Uncertain in the Research

The evidence is limited because many key trials are older, meaning they do not align with current standards for clinical research rigor. Additionally, the sample sizes were modest in some pivotal studies reviewed by scientific bodies. The certainty remains low because the findings for Dicyclomine have been mixed across different systematic reviews, and the evidence quality varies across studies. This means that the research provides context but not individual predictions regarding outcomes, and the evidence highlights what is known — and what is still uncertain — about the drug's role in spasm management.

Key Studies & References Irritable bowel syndrome in adults: diagnosis and management (NICE Clinical Guideline CG61)

Common questions about Спазго (FAQ)

Q: How quickly should someone expect Спазго to start working?

Official information indicates that after an oral dose of the active ingredient (Dicyclomine), peak levels in the body are typically reached within 60 to 90 minutes. This range describes the time it generally takes for the medicine to be most concentrated in the body following ingestion.

Q: How long does the effect of one dose of Спазго typically last?

The initial elimination half-life of the active ingredient is described in regulatory documents as approximately 1.8 hours. This suggests that the physiological effects of a single dose are relatively short-lived. Official guidelines support a dosing schedule of four times a day, which accounts for this duration.

Q: Can people take Спазго on an empty stomach?

Official product instructions indicate that this medication can be taken with or without food. However, for the liquid solution form, the regulatory label requires it to be diluted with an equal volume of water immediately prior to administration.

Q: Do all people who take Спазго experience side effects?

No. Clinical trial data examined in regulatory reviews showed that the most common side effects were reported by about 61% of patients. This indicates that a notable portion of people in the studies did not report these reactions. The appearance of adverse reactions is generally considered related to the dose used.

Q: What should a person do if they forget to take a dose of Спазго?

According to general administration guidelines, if a dose is missed, it should generally be omitted. The next administration should then occur at the regularly scheduled time. The guidance states that the dosage should not be doubled to compensate for the missed administration.

Q: Can Спазго be taken alongside pain relievers like ibuprofen?

Regulatory documents do not list a major, explicit interaction warning between the active ingredient (Dicyclomine) and common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, official label information highlights the importance of having all co-administered medications reviewed by a healthcare professional due to the potential for interactions.

Q: Can people with high blood pressure use Спазго?

Official safety warnings state that the drug is to be used with caution in people with hypertension (high blood pressure). This is because the medication can affect the cardiovascular system. Due to this potential, a healthcare professional assesses the appropriateness of use in this population.

Q: What happens if someone accidentally takes too much Спазго?

Taking too much of this medication can lead to an exaggeration of its anticholinergic effects. Serious symptoms noted in regulatory documents include psychosis, delirium, and a neuromuscular blockade. Any suspicion of an overdose is listed as a situation that requires immediate medical consultation or emergency care.

Q: Is it possible to be allergic to the ingredients in Спазго?

Yes. The official documentation lists hypersensitivity (an allergic reaction) to Dicyclomine hydrochloride or its other ingredients as a contraindication. This means that the official documentation establishes that the medicine is contraindicated when there is a known allergy to any component.

Q: Is Спазго available without a prescription?

No, according to its official marketing status, the active ingredient Dicyclomine hydrochloride is classified as a prescription-only (Rx) drug. It requires professional authorization because a qualified healthcare professional must assess its appropriate use and risks.

Q: Does Спазго interact with herbal supplements?

Regulatory summaries on Dicyclomine indicate that many drugs and herbal products may have the potential to affect its activity or vice versa. For this reason, official safety practice highlights the importance of full disclosure of all supplements to a healthcare professional for a complete review.

Q: Is Спазго used for headaches or migraines?

No. The official indications for this drug, as defined by regulatory bodies, state that it is only approved for the treatment of functional bowel disorders, such as Irritable Bowel Syndrome (IBS). It is not indicated for the management of headaches or migraines.

Q: What information should I provide to a healthcare professional before taking Спазго?

Official contraindications and warnings imply that specific information about pre-existing conditions is crucial for professional assessment. This includes a history of heart problems or high blood pressure, and especially conditions like glaucoma, myasthenia gravis, or obstructive diseases of the gastrointestinal or urinary tract. This information allows the professional to carry out a comprehensive assessment of eligibility and risk.

How to Store and Dispose of Spasgo (Dicyclomine Hydrochloride)

Spasgo must be stored according to specific regulatory requirements to maintain its stability and effectiveness. The product should be kept at a Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Storage requires protection from light, moisture, and excessive heat. The medicine must be dispensed in a tight, light-resistant container secured with a child-resistant closure, and it must always be kept out of the sight and reach of children and pets.

Disposal

Expired or unused Spasgo should be disposed of safely. The official recommendation is to utilize a local drug take-back program. Dicyclomine is not on the FDA list of medicines recommended for flushing; therefore, it should not be poured down the sink or toilet.